Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 2162-2164, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stieber, P.
Right arrow Articles by Domke, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stieber, P.
Right arrow Articles by Domke, I.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2001;47:2162-2164.)
© 2001 American Association for Clinical Chemistry, Inc.

Evaluation of the Analytical and Clinical Performance of the Elecsys® CA 15-3 Immunoassay

Petra Stieber1a, Rafael Molina2, Daniel W. Chan3, Herbert A. Fritsche4, Ralf Beyrau5, Jean M.G. Bonfrer6, Xavier Filella2, Terrie G. Gornet4, Torsten Hoff7, Wolfram Jäger8, Gerard J. van Kamp9, Dorothea Nagel1, Klaus Peisker10, Lori J. Sokoll3, Frédéric Troalen11, Michael Untch1 and Ingrid Domke12

1 Klinikum der Universität München Grosshadern, Institut für Klinische Chemie, Marchioninistrasse 15, D-81377 Munich, Germany;
2 Hospital Clinic I Provincial, Unitat de Recerca del Cancer, E-08034 Barcelona, Spain;
3 Johns Hopkins Medical Institutions, Department of Pathology, Clinical Chemistry Division, Baltimore, MD 21287-7065;
4 The University of Texas, MD Anderson Cancer Center, Section of Clinical Chemistry, Division of Pathology and Laboratory Medicine, Houston, TX 77030;
5 Institut für Klinische Chemie und Laboratoriumsdiagnostik, D-40225 Düsseldorf, Germany;
6 Antoni van Leeuwenhoek Hospital, NL-1066 CX Amsterdam, The Netherlands;
7 Zentralkrankenhaus Links der Weser, D-28277 Bremen, Germany;
8 Tumormarkerlabor, Universitätsfrauenklinik, D-91054 Erlangen, Germany;
9 Academisch Ziekenhuis, Vrije Universiteit, Centraal Chemisch Laboratorium, NL-1007 MB Amsterdam, The Netherlands;
10 St. Elisabeth Krankenhaus, D-06110 Halle, Germany;
11 Institut Gustave-Roussy, Departement de Biologie Clinique, F-94805 Villequif, France;
12 Roche Diagnostics GmbH, D-68305 Mannheim, Germany

aauthor for correspondence: fax 0-89-7095-6298, e-mail stieber@klch. med.uni-muenchen.de


   Introduction
 
Although the sensitivity and specificity of CA 15-3 in primary diagnosis of breast cancer is limited, CA 15-3 measurement has found widespread use in monitoring disease progression and response to therapy [reviewed in Ref. (1)]. A new assay for determination of CA 15-3 on Elecsys® immunoanalyzers has been introduced by Roche Diagnostics GmbH. The analytical performance of this assay was tested in an international multicenter evaluation in 11 evaluation sites, and the clinical performance was judged in 4 of these laboratories. The results are described in this report.

Elecsys CA 15-3 is a sandwich immunoassay that uses biotinylated 115D8 and ruthenylated DF3 as capture and detection antibodies, respectively, and electrochemiluminescence as the detection technology. Details of the test principle have been described previously (2). The test is standardized against the Enzymun-Test CA 15-3 (Roche Diagnostics GmbH) in the laboratories of the manufacturer.

The analytical evaluation was carried out according to a standardized protocol of the European Committee for Clinical Laboratory Standards (3). The results of within-run imprecision (21 replicates per analysis) and between-day imprecision (1 replicate analyzed on 21 different days) studies are available as a data supplement at Clinical Chemistry Online (http://www.clinchem.org/content/vol47/issue12). The medians of the within-run and between-day CVs were 2.5–3.8% and 5.0–5.9%, respectively, at all concentrations tested (8.4–251.7 kilounits/L) for human sera and control sera.

Confirmation of target values assigned to control sera was tested in an interlaboratory survey and was 97% for PreciControl Tumor Marker Level 1 (18.4 kilounits/L) and 96% for Level 2 (58.6 kilounits/L). The medians of all participants of an interlaboratory survey of the German Society for Clinical Chemistry were confirmed for each of the two control samples used (11.8 and 16.8 kilounits/L) by 99% (on the basis of the medians of all participants in . . . [Full Text of this Article]


   Acknowledgments
 

   References
 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.